A5078069424- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Cancer, Hypoxia, and Metabolism
- Peroxisome Proliferator-Activated Receptors
- Diabetes Treatment and Management
- Immune cells in cancer
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Cell Image Analysis Techniques
- AI in cancer detection
- Pancreatic and Hepatic Oncology Research
- Nanoplatforms for cancer theranostics
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Melanoma and MAPK Pathways
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Advanced Biosensing Techniques and Applications
- Cell Adhesion Molecules Research
- vaccines and immunoinformatics approaches
- Monoclonal and Polyclonal Antibodies Research
Columbia University Irving Medical Center
2016-2025
Albert Einstein College of Medicine
2020-2025
Montefiore Einstein Comprehensive Cancer Center
2024-2025
Montefiore Medical Center
2020-2025
Jacobi Medical Center
2024
Columbia University
2013-2022
Columbia College
2014-2022
Royal College of Physicians
2014-2022
Herbert Irving Comprehensive Cancer Center
2022
National Center on Addiction and Substance Abuse at Columbia University
2019-2022
Acute graft-versus-host disease (GVHD) results from the attack of host tissues by donor allogeneic T cells and is most serious limitation hematopoietic cell transplantation (allo-HCT). Host antigen-presenting are thought to control priming alloreactive induction acute GVHD after allo-HCT. However, whereas role DC in has been established, contribution macrophages not clearly addressed. We show that, contrast DC, reducing macrophage pool recipient mice increased expansion aggravated mortality...
Abstract Purpose: Polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose (poly-ICLC), a synthetic double-stranded RNA complex, is ligand for toll-like receptor-3 and MDA-5 that can activate immune cells, such as dendritic trigger natural killer cells to kill tumor cells. Patients Methods: In this pilot study, eligible patients included those with recurrent metastatic disease in whom prior systemic therapy (head neck squamous cell cancer melanoma) failed. received 2 treatment...
Novel methods to analyze the tumor microenvironment (TME) are urgently needed stratify melanoma patients for adjuvant immunotherapy. Tumor-infiltrating lymphocyte (TIL) analysis, by conventional pathologic methods, is predictive but insufficiently precise clinical application. Quantitative multiplex immunofluorescence (qmIF) allows evaluation of TME using multiparameter phenotyping, tissue segmentation, and quantitative spatial analysis (qSA). Given that CD3+CD8+ cytotoxic lymphocytes (CTLs)...
Abstract Purpose: Biomarkers for disease-specific survival (DSS) in early-stage melanoma are needed to select patients adjuvant immunotherapy and accelerate clinical trial design. We present a pathology-based computational method using deep neural network architecture DSS prediction. Experimental Design: The model was trained on 108 from four institutions tested 104 Yale School of Medicine (YSM, New Haven, CT). A receiver operating characteristic (ROC) curve generated the basis vote...
Abstract Assessment of tumor infiltrating lymphocytes (TILs) as a prognostic variable in melanoma has not seen broad adoption due to lack standardization. Automation could represent solution. Here, using open source software, we build an algorithm for image-based automated assessment TILs on hematoxylin-eosin stained sections melanoma. Using retrospective collection 641 patients comprising four independent cohorts; one training set (N = 227) and three validation cohorts 137, N 201, 76) from...
Non-recirculating tissue-resident memory T cells (TRMs) are the predominant cell subset in diverse tissue sites, where they mediate protective immune responses situ. Here, we reveal a role for TRM maintaining homeostasis human pancreas through interactions with resident macrophages and PD-1/PD-L1 inhibitory pathway. Using tissues obtained from organ donors, identify that comprise CD8+PD-1hi TRMs, which phenotypically, functionally, transcriptionally distinct compared to TRMs neighboring...
<h3>Background</h3> Chemoradiotherapy (CRT) remains one of the most common cancer treatment modalities, and recent data suggest that CRT is maximally effective when there generation an anti-tumoral immune response. However, has also been shown to promote immunosuppressive mechanisms which must be blocked or reversed maximize its stimulating effects. <h3>Methods</h3> Therefore, using a preclinical model human papillomavirus (HPV)-associated head neck squamous cell carcinoma (HNSCC), we...
<h3>Background</h3> Immune checkpoint inhibitors (ICIs) for solid tumors, including those targeting programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have shown impressive clinical efficacy, however, most patients do not achieve durable responses. One major therapeutic obstacle is the immunosuppressive tumor immune microenvironment (TIME). Thus, we hypothesized that a strategy combining tumor-directed radiation with TIME immunomodulation could improve...
Background: : Incidence of hepatocellular cancer (HCC) in the Bronx is 61% higher than rest New York State. Underserved populations are not well represented clinical trials immune checkpoint inhibitors (ICI). Methods: Demographics were tabulated for 194 patients treated with ICI at Montefiore-Einstein Comprehensive Cancer Center (MECCC) between 2017 and 2022. Categorical variables analyzed by Chi-squared test, survival was using Kaplan–Meier (KM) curves. Results: MECCC 40.7% Hispanic 20.6%...
TPST-1120 is a first-in-class oral inhibitor of peroxisome proliferator-activated receptor α (PPARα), fatty acid ligand-activated transcription factor that regulates genes involved in oxidation, angiogenesis, and inflammation, novel target for cancer therapy. displayed antitumor activity xenograft models synergistic tumor reduction syngeneic when combined with anti-PD-1 agents.
671 Background: Neuroendocrine tumors (NETs) pose different clinical implications based upon age at diagnosis, with regards to early-onset (EO<50yrs) versus late-onset (LO>=50yrs) disease. While primary-tumor resection is crucial for localized NETs, its benefit in metastatic cases without metastasectomy remains uncertain. This study examines variables associated survival EO LO cases, including primary tumor resection. Methods: A retrospective cohort of 91 patients...
105 Background: Despite the declining incidence rates (IR) in average onset colon cancer (AO-CC), IR for early (EO-CC), defined as patients (pts) younger than 50-years-old at diagnosis, has been increasing. Treatment high risk locally advanced (CC) is surgical resection followed by adjuvant chemotherapy (AC). Data indicates a more permissive use EO-CC. There limited data about treatment and survival trends Thus, we aimed to assess benefit of AC between EO vs AO CC disease. Methods: diagnosed...
294 Background: Irinotecan is a widely used and effective treatment for various gastrointestinal malignancies. Its toxic metabolite, SN-38, inactivated by UDP glucuronosyltransferase-1A1 (UGT1A1). However, variability in individual clearance of irinotecan SN-38 can cause unpredictable toxicities. Mutations the UGT1A1 gene reduces enzyme activity, resulting dose-limiting neutropenia diarrhea, hospitalizations, delays, dose reductions. The best characterized germline variant polymorphism...